Description

Commercial Opportunity
The anti-TACE antibody comes with an extensive package of data demonstrating high affinity binding, potent inhibitory action against TACE in-vitro and in-vivo, a long in-vivo half-life and in-vivo efficacy in a cancer xenograft model. The antibody is a fully human IgG1 and represents a potential clinical candidate providing a unique opportunity for rapid development of this first-in-class antibody into the clinic in a short timescale.

In addition to utility in a range of common cancer types, there are clear links between TACE and a number of infl ammatory indications such as rheumatoid arthritis and psoriasis where specific inhibition of TACE may be of value. CRT is seeking a licensee to take the antibody forward into clinical development.

Download the PDF of First-in-class antagonistic TACE antibody

For more information please contact

Dr Angus Lauder

+44 (0) 20 3469 6300 .(JavaScript must be enabled to view this email address)